Skip to content

Checked

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

NCT07128680 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 1
Interventional
Planned enrollment
33
Participants, all sites
U.S. sites
2
In 1 state

Study details

Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Sponsor
City of Hope Medical Center (University, hospital or other organization)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
03/23/2026
Primary completion (expected)
08/25/2028
Last updated by sponsor
07/16/2026

Full eligibility rules, contacts and site names: NCT07128680 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Duarte, Irvine

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 07/16/2026